Insider trade

Director received an award of 105 BDX derivative securities

Traded May 8, 2026 · Filed May 8, 2026

Becton DickinsonBDX

105
Derivative units · @ $149.04

Why it stands out

Compensation award — excluded from discretionary-purchase analysis.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: May 8, 2026
Reporting period: Not applicable
Filed with the SEC: May 8, 2026

DirectorGrant / award

Context

Classification

grant award

Code A — grant or award

Planned / mechanical clue

Footnote references dividend reinvestment

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001628280-26-033022
Filed / recorded

May 8, 2026, 9:25 PM UTC

Added to OQRO

Oct 2, 2026, 12:27 PM UTC

Parser

form4-xml-v1

Data quality

Verified: identifiers matched exactly

Issuer

BECTON DICKINSON & CO

Issuer CIK

10795

Ticker

BDX

Reporting person

Carrie L Byington

Relationship

Director

Security

Rights to Common Stock Under BD Deferred Compensation Plan

Table

Derivative (Table II)

Transaction date

May 8, 2026

Transaction code

A

Shares / units

105

Price per share

$149.04

Acquired / disposed

Acquired (A)

Shares owned after

3,699

Ownership form

Direct

Amendment

No

Footnotes from the filing

The securities convert to common stock on a one-for-one basis.
The securities are distributed following termination of the reporting person's service as a director, or on the date or dates specified by the reporting person.
Includes rights acquired through dividend reinvestment since the last report filed by the reporting person.
Reflects the adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. to the number of previously reported derivative securities held by the reporting person.